Proposed Data Collections Submitted for Public Comment and Recommendations, 71537-71538 [E5-6671]
Download as PDF
<![CDATA[
71537
Federal Register / Vol. 70, No. 228 / Tuesday, November 29, 2005 / Notices
difference between the type of original
researcher (e.g., academic or non-profit)
on maintenance and fidelity; (f)
identification of perceived and actual
benefits as well as instrumental and
conceptual utility of REP-packaged
interventions that can be used in
marketing the intervention packages to
other HIV prevention providers.
Researchers administering the in-person
surveys will also assess fidelity to
intervention protocols by observing
facilitators delivering the intervention
to (a) identification of factors associated
with maintenance and termination of
REP-packaged interventions; (b)
determination of why and how agencies
adapted the packaged interventions; (c)
examination of the impact of elapsed
time on maintenance of the intervention
and fidelity to intervention protocols;
(d) identification of any differences
between the type of agency (e.g.,
community-based organization or health
department) on maintenance and
fidelity; (e) identification of any
and by recording their observations on
a checklist designed for the particular
intervention being observed.
Survey questionnaire data will be
collected once from each respondent
(i.e., agency administrator, intervention
supervisor, intervention facilitator).
CDC is requesting OMB approval to
collect this data for one year. There are
no costs to the respondents other than
their time. Total burden hours for this
data collection are 105 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Agency Administrators (content review) ....................................................................
Agency Administrators (questionnaire) ......................................................................
Intervention Supervisors ............................................................................................
Intervention Facilitators ..............................................................................................
Dated: November 18, 2005.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E5–6670 Filed 11–28–05; 8:45 am]
BILLING CODE 4163–18–P
16
16
15
30
mail to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.
Proposed Project
Health Communication Planning,
Implementation, and Evaluation for
People with Disabilities—New—
National Center on Birth Defects and
Developmental Disabilities (NCBDDD),
Centers for Disease Control and
Prevention (CDC).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–06–05AO]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–4766 or send an e-
Number of responses per respondent
Number of
respondents
Respondents
Background and Brief Description
The National Center on Birth Defects
and Developmental Disabilities
(NCBDDD) at CDC promotes the health
of babies, children, and adults with
disabilities. As part of these efforts the
Center is actively involved in improving
the health and wellness of people with
disabilities. Of particular interest is how
health information is communicated to
people with disabilities. This project
involves the conduct of an e-mail survey
Average burden
per response
(in hours)
1
1
1
1
20/60
1.5
1.5
1.75
for an initiative evaluating the
effectiveness of health communication
materials and strategies developed for
people with disabilities by North
Carolina, New Mexico, and New York
with the support of health promotion
grants from CDC. The survey data will
be analyzed to evaluate awareness of the
state-developed materials among health
care providers, human services
providers and consumer advocates
using these materials, their impressions
of and satisfaction with the materials,
the impact of the materials, and
suggestions for improvement. Data will
be collected using an on-line selfreporting survey distributed via e-mail
and administered by linking to a webbased questionnaire. The results will be
used to develop a training handbook to
assist state agencies and public health
officials in planning, developing, and
implementing health communication
materials for people with disabilities.
There are no costs to respondents except
their time to participate in the survey.
The total estimated annualized burden
hours are 45.
ESTIMATE OF ANNUALIZED BURDEN HOURS
No. of
respondents
Type of respondents
Health Care Providers ...............................................................................................
Human Services Providers ........................................................................................
Consumer Advocates ................................................................................................
VerDate Aug<31>2005
20:13 Nov 28, 2005
Jkt 208001
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
No. of responses
per respondent
50
50
50
E:\FR\FM\29NON1.SGM
1
1
1
29NON1
Average burden
per response
(in hours)
18/60
18/60
18/60
71538
Federal Register / Vol. 70, No. 228 / Tuesday, November 29, 2005 / Notices
Dated: November 18, 2005.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E5–6671 Filed 11–28–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control.
[FR Doc. 05–23425 Filed 11–28–05; 8:45 am]
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
Breast and Cervical Cancer Early
Detection and Control Advisory
Committee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting:
Name: Breast and Cervical Cancer
Early Detection and Control Advisory
Committee (BCCEDCAC).
Times and Dates: 8:30 a.m.–5 p.m.,
December 6, 2005. 8:30 a.m.–1 p.m.,
December 7, 2005.
Place: Embassy Suites Hotel,
Centennial Olympic Park, 267 Marietta
Street, Atlanta, Georgia 30313.
Phone: 1–404–223–2300.
Status: Open to the public, limited
only by the space available.
Purpose: The committee is charged
with advising the Secretary, Department
of Health and Human Services, and the
Director, CDC, regarding the early
detection and control of breast and
cervical cancer. The committee makes
recommendations regarding national
program goals and objectives;
implementation strategies; and program
priorities including surveillance,
epidemiologic investigations, education
and training, information dissemination,
professional interactions and
collaborations, and policy.
Matters to be Discussed: The agenda
will include discussion and review of
the vision for National Cancer
Prevention and Control Program;
strategies for Performance-Based
Funding; Case Management; update of
expert panel meetings; HPV Testing and
the Breast and Cervical Program; and
HPV Vaccine update.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Debra Younginer, Executive Secretary,
BCCEDCAC, Division of Cancer
Prevention and Control, National Center
for Chronic Disease Prevention and
Health Promotion, CDC, 4770 Buford
Highway, Mailstop K–57, Chamblee,
Georgia 30316, Telephone: 770–488–
1074.
VerDate Aug<31>2005
20:13 Nov 28, 2005
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0374]
Nonprescription Drugs Advisory
Committee and Pulmonary-Allergy
Drugs Advisory Committee; Notice of
Meeting and Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committees:
Nonprescription Drugs Advisory
Committee and the Pulmonary-Allergy
Drugs Advisory Committee.
General Function of the Committees:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on January 24, 2006, from 8 a.m.
to 5 p.m. Interested persons and
organizations may submit written or
electronic comments until January 6,
2006, to the Division of Dockets
Management (see Addresses).
Addresses: Electronic comments
should be submitted to https://
www.fda.gov/dockets/ecomments.
Select ‘‘2005N–0374 Use of OzoneDepleting Substance: Essential-Use
Determination of Over-the-Counter
(OTC) Epinephrine Metered Dose
Inhalers’’ and follow the prompts to
submit your statement. Written
comments should be submitted to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
Location: Holiday Inn Select
Bethesda, The Ballrooms, 8120
Wisconsin Ave., Bethesda, MD. The
hotel telephone number is 301–652–
2000.
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
Contact Person: Darrell Lyons, Center
for Drug Evaluation and Research (HFD
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, rm. 1093) Rockville,
MD 20857, (301–827–7001, FAX: 301–
827–6776, e-mail: lyonsd@cder.fda.gov,
or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area) codes 3014512541 or 3014512545.
Please call the Information Line for up
to date information on this meeting.
Agenda: The committee will discuss
the continued need for the designation
of OTC epinephrine-metered dose
inhalers for the treatment of asthma as
an essential use of ozone-depleting
substances (ODSs) under § 2.125 (21
CFR 2.125). ODSs are substances that
deplete the stratospheric ozone, which
include chlorofluorocarbons (CFCs).
Once released, CFCs rise to the
stratosphere. In the stratosphere, CFCs
are gradually broken down by strong
ultraviolet light, and they release
chlorine atoms that then deplete
stratospheric ozone. Depletion of
stratospheric ozone by CFCs and other
ODSs leads to higher ultraviolet B
radiation levels, which in turn increase
skin cancers and cataracts, as well as
cause other significant environmental
damage.
FDA is soliciting comments and data
to support or refute an essential-use
designation for OTC epinephrine
metered-dose inhaler (MDI) drug
products. These products include the
only OTC drug available in an MDI
dosage form for the treatment of asthma.
The OTC epinephrine MDIs use CFCs as
propellants. The OTC indication is ‘‘for
temporary relief of shortness of breath,
tightness of chest, and wheezing due to
bronchial asthma.’’ In some instances,
use of this product early during an
asthma attack could avert a serious or
life-threatening worsening of the attack.
There are currently a limited number of
marketed OTC drug products containing
epinephrine in a MDI dosage form.
According to § 2.125(f)(1), the
following are criteria for continued ODS
essential-use designation:
(1) Substantial technical barriers exist
to formulating the product without
ODSs;
(2) The product will provide an
otherwise unavailable important public
health benefit; and
(3) Use of the product does not release
cumulative significant amounts of ODSs
into the atmosphere or the release is
warranted in view of the high
E:\FR\FM\29NON1.SGM
29NON1
]]>Agencies
[Federal Register Volume 70, Number 228 (Tuesday, November 29, 2005)]
[Notices]
[Pages 71537-71538]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-6671]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-06-05AO]
Proposed Data Collections Submitted for Public Comment and
Recommendations
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-4766 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-6974.
Written comments should be received within 30 days of this notice.
Proposed Project
Health Communication Planning, Implementation, and Evaluation for
People with Disabilities--New--National Center on Birth Defects and
Developmental Disabilities (NCBDDD), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The National Center on Birth Defects and Developmental Disabilities
(NCBDDD) at CDC promotes the health of babies, children, and adults
with disabilities. As part of these efforts the Center is actively
involved in improving the health and wellness of people with
disabilities. Of particular interest is how health information is
communicated to people with disabilities. This project involves the
conduct of an e-mail survey for an initiative evaluating the
effectiveness of health communication materials and strategies
developed for people with disabilities by North Carolina, New Mexico,
and New York with the support of health promotion grants from CDC. The
survey data will be analyzed to evaluate awareness of the state-
developed materials among health care providers, human services
providers and consumer advocates using these materials, their
impressions of and satisfaction with the materials, the impact of the
materials, and suggestions for improvement. Data will be collected
using an on-line self-reporting survey distributed via e-mail and
administered by linking to a web-based questionnaire. The results will
be used to develop a training handbook to assist state agencies and
public health officials in planning, developing, and implementing
health communication materials for people with disabilities. There are
no costs to respondents except their time to participate in the survey.
The total estimated annualized burden hours are 45.
Estimate of Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average burden
Type of respondents No. of No. of responses per response (in
respondents per respondent hours)
----------------------------------------------------------------------------------------------------------------
Health Care Providers.................................. 50 1 18/60
Human Services Providers............................... 50 1 18/60
Consumer Advocates..................................... 50 1 18/60
----------------------------------------------------------------------------------------------------------------
[[Page 71538]]
Dated: November 18, 2005.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E5-6671 Filed 11-28-05; 8:45 am]
BILLING CODE 4163-18-P
